Acorda Therapeutics (ACOR +1.9%) hits new 52-week highs after it reported better-than-expected...

|About: Acorda Therapeutics, Inc. (ACOR)|By:, SA News Editor

Acorda Therapeutics (ACOR +1.9%) hits new 52-week highs after it reported better-than-expected results for Q4. Revenue for the quarter came in at $81.5 million, beating the $78.90 million consensus. Additonally, the company says it plans to submit an NDA to the FDA for a diazepam nasal spray in 2013.